The Coalition for Epidemic Preparedness Innovations (CEPI) has earmarked up to $384m in additional funding for a Novavax coronavirus vaccine candidate due to start trials this month. CEPI had already pledged $4m to the development of NVX-CoV2373 in March, and the scale of the new investment – the highest so far for any CEPI-backed programme – immediately elevates the candidate to the top tier among vaccines against SARS-CoV-2, the virus that causes COVID-19. Source: PMLive 12/5/2020